Unraveling the complexity of PD-L1 assays: a descriptive review of the methodology, scoring, and practical implications
Bibliographic record
Abstract
Purpose: Over the years, immune checkpoint inhibitors targeting the programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) axes have substantially improved clinical outcomes for patients with various types of cancer and stages. As a result, PD-L1 is the most recognized biomarker used to guide the selection of patients for treatment with anti-PD-(L)1 therapy. To date, there are 4 regulatory agency-approved and commercially available immunohistochemistry assays used to quantify PD-L1 tumor expression, with each assay approved for use with a specific PD-(L)1 inhibitor. In this descriptive review, we concisely summarize the methodology and scoring methods of each assay, as well as some of the challenges associated with real-world use of these assay systems. Results: Each assay system is optimized for specific therapies, with its own anti-PD-L1 antibody, protocol, scoring, and interpretation guidelines. Although the methodologies of the 4 PD-L1 immunohistochemistry assay systems are similar, differences in their antibody clones, protocol conditions, instrumentation, and scoring methods limit assay interchangeability. The assays are also highly sensitive; slight deviations to the protocol can increase the risk of misclassifying the PD-(L)1 tumor status of patients. As a result, pathologists are faced with choosing which assay to perform with a limited tumor sample as well as with the challenges associated with the scoring methods and differences in regional regulatory approvals and infrastructure. Conclusion: While the 4 approved PD-L1 immunohistochemistry assays provide clinical value, we offer pathologists suggestions to reduce the challenges associated with PD-L1 testing based on assay systems.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.016 | 0.022 |
| Meta-epidemiology (narrow) | 0.002 | 0.001 |
| Meta-epidemiology (broad) | 0.002 | 0.002 |
| Bibliometrics | 0.008 | 0.005 |
| Science and technology studies | 0.001 | 0.004 |
| Scholarly communication | 0.004 | 0.005 |
| Open science | 0.003 | 0.001 |
| Research integrity | 0.002 | 0.006 |
| Insufficient payload (model declined to judge) | 0.001 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".